Baxter International Inc. (NYSE:BAX) Shares Bought by CKW Financial Group

CKW Financial Group grew its holdings in shares of Baxter International Inc. (NYSE:BAX) by 19.3% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 2,625 shares of the medical instruments supplier’s stock after acquiring an additional 425 shares during the quarter. CKW Financial Group’s holdings in Baxter International were worth $77,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in BAX. First PREMIER Bank bought a new stake in shares of Baxter International in the 3rd quarter worth $25,000. Fortitude Family Office LLC bought a new stake in shares of Baxter International in the 3rd quarter worth $38,000. LRI Investments LLC raised its stake in shares of Baxter International by 60.8% in the 3rd quarter. LRI Investments LLC now owns 1,560 shares of the medical instruments supplier’s stock worth $59,000 after buying an additional 590 shares in the last quarter. Cromwell Holdings LLC bought a new stake in shares of Baxter International in the 3rd quarter worth $62,000. Finally, Bruce G. Allen Investments LLC raised its stake in shares of Baxter International by 247.3% in the 4th quarter. Bruce G. Allen Investments LLC now owns 2,622 shares of the medical instruments supplier’s stock worth $76,000 after buying an additional 1,867 shares in the last quarter. Institutional investors and hedge funds own 90.19% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. StockNews.com downgraded Baxter International from a “buy” rating to a “hold” rating in a research note on Monday, November 11th. Stifel Nicolaus dropped their price objective on Baxter International from $46.00 to $38.00 and set a “buy” rating on the stock in a research note on Monday, November 11th. Finally, Citigroup dropped their price objective on Baxter International from $37.00 to $35.00 and set a “neutral” rating on the stock in a research note on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $40.45.

Baxter International Stock Down 0.0 %

NYSE:BAX opened at $32.45 on Monday. The firm has a market capitalization of $16.57 billion, a price-to-earnings ratio of 162.23, a PEG ratio of 10.15 and a beta of 0.59. Baxter International Inc. has a 1-year low of $28.33 and a 1-year high of $44.01. The company has a current ratio of 1.43, a quick ratio of 1.09 and a debt-to-equity ratio of 1.31. The business’s fifty day moving average price is $30.97 and its 200 day moving average price is $34.64.

Baxter International (NYSE:BAX) last posted its quarterly earnings results on Friday, November 8th. The medical instruments supplier reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.78 by $0.02. The firm had revenue of $3.85 billion for the quarter, compared to analyst estimates of $3.85 billion. Baxter International had a return on equity of 18.30% and a net margin of 0.77%. Baxter International’s quarterly revenue was up 3.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.68 earnings per share. On average, sell-side analysts forecast that Baxter International Inc. will post 1.83 earnings per share for the current fiscal year.

Baxter International Cuts Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, January 2nd. Investors of record on Friday, November 29th were given a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a yield of 2.10%. The ex-dividend date of this dividend was Friday, November 29th. Baxter International’s payout ratio is 340.02%.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.